Is Cytokinetics, Incorporated (CYTK) A Good Stock To Buy Now?
Is CYTK a good stock to buy? We came across a bullish thesis on Cytokinetics, Incorporated on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on CYTK.
Cytokinetics Inc (CYTK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 3,333,333 | $219,699,978 | 2.16% | |
| 2. | 1,700,000 | $112,047,000 | +14% | 1.99% | |
| 3. | Polar Capital Brian Ashford-Russell And Tim Woolley | 1,661,248 | $109,492,856 | -32% | 0.39% |
| 4. | Integral Health Asset Management Bhagwan Jay Rao | 1,600,000 | $105,456,000 | +15% | 5.04% |
| 5. | Paradigm Biocapital Advisors Senai Asefaw | 1,480,857 | $97,603,285 | 1.99% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.57 | 6,000 | $51,426.60 | 6,250 | 2019-11-19 | Filing | |
| $9.52 | 8,506 | $80,934.59 | 499,312 | 2019-12-11 | Filing | |
| $9.52 | 49,804 | $473,885.06 | 2,861,622 | 2019-12-11 | Filing | |
| $9.52 | 60,103 | $571,880.05 | 3,617,776 | 2019-12-11 | Filing | |
| $9.40 | 15,030 | $141,282.00 | 490,806 | 2019-12-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.02 | 7,490 | $614,329.80 | 377,820 | 2026-07-13 | Filing | |
| $82.02 | 10 | $820.20 | 377,820 | 2026-07-13 | Filing | |
| $86.62 | 3,500 | $303,170.00 | 153,902 | 2026-07-07 | Filing | |
| $84.92 | 7,500 | $636,900.00 | 377,830 | 2026-07-01 | Filing | |
| $85.80 | 15,000 | $1,287,000.00 | 58,555 | 2026-07-01 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 304,611 | $25,949,811 | 0.6% | |
| 2. | 202,370 | $17,239,900 | 2.11% | |
| 3. | 100,019 | $8,520,619 | 0.28% | |
| 4. | 43,619 | $3,715,903 | 0.07% | |
| 5. | 38,651 | $3,292,679 | 0.04% |
News See All
10 Most Promising Mid-Cap Stocks to Buy According to Analysts
On June 9, Liz Ann Sonders, Charles Schwab, joined 'Closing Bell' on CNBC to discuss the recent market movements, suggesting that the recent sell-off helped alleviate some of the market's overbought characteristics...
Citi Calls Cytokinetics, Incorporated (CYTK) a "Top Pick" Among Small-to-Mid Cap Biotech Stocks
Cytokinetics, Incorporated (NASDAQ:CYTK) is one of the best momentum stocks to buy according to analysts. Citi initiated coverage of Cytokinetics, Incorporated (NASDAQ:CYTK) with a Buy rating on May ...
10 Best Momentum Stocks to Buy According to Analysts
On May 22, Steve Sosnick, from Interactive Brokers, appeared on CNBC’s ‘Power Lunch’ to talk about what is driving the record market moves.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2026 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2026 Earnings Call Transcript May 5, 2026Cytokinetics, Incorporated reports earnings inline with expectations.
10 Stocks Turning Heads With Double-Digit Gains
The stocks mirrored a broader market optimism, with Wall Street’s three major indices finishing in the green.
Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2025 Earnings Call Transcript
Cytokinetics, Incorporated (NASDAQ:CYTK) Q4 2025 Earnings Call Transcript February 24, 2026Cytokinetics, Incorporated misses on earnings expectations.
Cytokinetics, Incorporated (CYTK) Poised for Market Share Gain with Myqorzo in Cardiac Myosin Space
Cytokinetics (NASDAQ:CYTK) is one of the best debt-free mid-cap stocks to buy according to hedge funds. On February 4, B.
10 Best Debt-Free Mid-Cap Stocks to Buy According to Hedge Funds
Mid-cap stocks are poised for an impressive run heading into the US midterm election.
Truist Notes Operational Investments For Cytokinetics, Incorporated (CYTK) to Support Short-Term Growth
TheFly reported on February 3 that Truist raised its price target on CYTK to $92 from $84 and maintained a Buy rating. The company revised its model ahead of its Q4 results to account for the impact...